Market

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‘Cell Lymphoma CD5 CAR-NK Therapy

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‘Cell Lymphoma CD5 CAR-NK Therapy
Read More

Related Posts

Why Nvidia earnings report is good news for its Big Tech rivals

Why Nvidia earnings report is good news for its Big Tec...

Dollar firms as Trump's tariffs loom, yen set for monthly gain

Dollar firms as Trump's tariffs loom, yen set for month...

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...

Alliance Entertainment CEO Jeffrey Walker buys $2.69 billion in stock

Alliance Entertainment CEO Jeffrey Walker buys $2.69 bi...

Home-builder ETFs down in 2025 after brutal February as these worries weigh

Home-builder ETFs down in 2025 after brutal February as...

Csg Systems director Ronald Cooper sells $599,580 in stock

Csg Systems director Ronald Cooper sells $599,580 in stock